NCT02614859View on ClinicalTrials.gov

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

January 24, 2020

Study Completion Date

January 24, 2020

Conditions
Cancer of Prostate
Interventions
DRUG

Observation and Bicalutamide

Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).

DRUG

Metformin and Bicalutamide

Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID

Trial Locations (2)

20892-9760

National Cancer Institute, Bethesda

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT02614859 - Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients | Biotech Hunter | Biotech Hunter